Publication: 2026

Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial
      QxMD      Google Scholar   
Citation:
Lancet Oncol vol 14 (13) 1317-1325
Year:
2013
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
Received
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
3
Parents:
418   965  
Children:
None
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
 
Grants:
CA33601, U10 CA76001, U10 CA031946, U10 CA033601, P30 CA015083, U10 CA076001, CA31946  
Corr. Author:
 
Authors:
                       
Networks:
 
Study
ACOSOG-Z1041
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
Article